Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808415 | 0.90 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL7476046 | 0.87 | KMT2A (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1809242 | 0.85 | NPC1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL14149444 | 0.78 | HCAR2 (0.53) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1808675 | 0.77 | S1PR1 (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3511939 | 0.77 | KDM4C (0.56) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL9533696 | 0.76 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11971241 | 0.76 | NPC1 (0.43) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5823357 | 0.76 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4152979 | 0.74 | KDM4C (0.53) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| EP-3056485-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2018-05-09 | — | — | EP | disclosed |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2017-09-14 | — | — | US | disclosed |
| US-9657003-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2017-05-23 | — | — | US | disclosed |
| EP-3056485-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2016-08-17 | — | — | EP | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MEN1 1934/4885KMT2A 3516/4885KDM4C 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.